In the face of a disease that has already claimed more than a thousand lives across Africa this year, the World Health Organization has moved to distribute nearly 900,000 mpox vaccine doses to nine nations bearing the heaviest burden of the outbreak. The Democratic Republic of Congo, where a new and more transmissible variant first emerged and where the toll has been most severe, will receive the vast majority of the supply. This allocation — drawn from donors across Europe, North America, and the Gavi partnership — represents humanity's attempt to close the distance between a crisis already u
WHO allocates 899,000 mpox vaccine doses to nine hardest-hit African nations
More than 1,000 deaths from mpox reported across Africa this year, with over 46,000 confirmed and suspected cases.
The DRC will receive 85 percent of the allocated doses, reflecting where the outbreak has been most severe.
Mark
Why did it take until August for the WHO to declare this a global emergency, given that cases were spreading across borders?
Mimi
The variant itself—clade Ib—was new and its transmissibility wasn't immediately clear. Early cases were contained or manageable. Once it began moving from the DRC into neighboring countries with sustained chains of transmission, the scale of the threat became undeniable.
Mark
The DRC is getting 85 percent of the doses. Does that mean the other eight countries are getting shortchanged?
Mimi
Not necessarily. The allocation reflects where the outbreak is most severe. But it does mean those other countries are betting on a combination of their own vaccine supplies, if they have them, and the doses they're receiving here. It's a triage approach.
Mark
Why did the WHO face criticism for moving slowly on vaccines?
Mimi
There's always tension between caution—making sure a vaccine is safe and effective—and speed. In a crisis, people want doses available immediately. The WHO had to balance regulatory rigor with the urgency of an outbreak that was killing people.
Mark
Is 900,000 doses enough to stop this outbreak?
Mimi
It's a start, not a finish line. Africa's population is over a billion. You're looking at targeted vaccination of high-risk groups and contacts, not mass immunization. The real question is whether this slows transmission enough to prevent the variant from becoming entrenched.
Mark
What happens if these doses run out before the outbreak is controlled?
Mimi
Then you're back to requesting more from donors, hoping manufacturing can scale up, and relying on other tools—testing, isolation, treatment—to manage cases. It's why the WHO set up that broader support scheme beyond just vaccines.
The Pulse
- A new mpox variant, clade Ib, crossed borders out of the DRC with enough speed and severity that the WHO declared a global health emergency in August — its second such declaration for mpox in two years.
- With over 46,000 confirmed and suspected cases and more than 1,000 deaths recorded across Africa in 2024, the window for meaningful containment is visibly narrowing.
- The WHO had already drawn criticism for a slow initial vaccine response, and only cleared its first mpox vaccine for emergency use in September, adding urgency and scrutiny to every subsequent move.
- Nearly 900,000 doses are now being directed to nine countries — the DRC absorbing 85 percent — sourced from a coalition of European nations, the United States, Canada, and Gavi.
- Whether this effort succeeds will hinge not just on dose availability but on whether fragile health systems can deliver, track, and sustain vaccination campaigns fast enough to bend the outbreak's trajectory.
In the face of a disease that has already claimed more than a thousand lives across Africa this year, the World Health Organization has moved to distribute nearly 900,000 mpox vaccine doses to nine nations bearing the heaviest burden of the outbreak. The Democratic Republic of Congo, where a new and more transmissible variant first emerged and where the toll has been most severe, will receive the vast majority of the supply. This allocation — drawn from donors across Europe, North America, and the Gavi partnership — represents humanity's attempt to close the distance between a crisis already unfolding and the tools capable of slowing it.
The World Health Organization announced this week the allocation of nearly 900,000 mpox vaccine doses across nine African nations — the Central African Republic, Ivory Coast, the Democratic Republic of Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa, and Uganda — each confronting a surge that has grown increasingly difficult to contain.
The crisis sharpened in August, when the WHO declared mpox a global public-health emergency for the second time in two years. The trigger was clade Ib, a new variant that originated in the DRC and began spreading into neighboring countries, alarming health officials with its transmission potential. Africa has since recorded more than 46,000 confirmed and suspected cases, and more than 1,000 deaths.
The DRC, as the epicenter of the outbreak, will receive 85 percent of the allocated doses — a distribution that mirrors the epidemiological weight the country carries. The remaining doses will be divided among the eight other nations. Vaccines have been sourced from European countries, the United States, Canada, and Gavi, the public-private partnership that has long helped channel medical resources to lower-income nations.
The announcement follows a period of sustained criticism aimed at the WHO for what many characterized as a delayed response. The organization cleared Bavarian Nordic's mpox vaccine for emergency use in September and signaled it was also evaluating a Japanese-developed alternative, expanding the options available to affected countries.
The deeper challenge now is delivery. Doses reaching these nine countries must be administered quickly to healthcare workers, close contacts, and communities with active transmission — and the health systems responsible for that work vary widely in their capacity to execute, monitor, and adapt as the outbreak continues to evolve.
The World Health Organization moved to distribute nearly 900,000 vaccine doses across nine African nations this week, marking a significant escalation in the global response to an outbreak that has already killed more than 1,000 people on the continent. The allocation targets the countries facing the fiercest surge of mpox—the Central African Republic, Ivory Coast, the Democratic Republic of Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa, and Uganda—each of which has reported substantial caseloads in recent months.
The timing reflects the urgency of a crisis that intensified dramatically in August, when the WHO declared mpox a global public-health emergency for the second time in two years. That declaration came after a new variant, clade Ib, began spreading from the Democratic Republic of Congo into neighboring territories, triggering alarm among health officials who recognized the threat of rapid transmission across borders. By the time the vaccine allocation was announced on Wednesday, Africa had already recorded more than 46,000 confirmed and suspected cases of the disease.
The Democratic Republic of Congo, where the outbreak originated and where transmission has been most severe, will receive the lion's share of the vaccine supply—85 percent of the total allocation. This concentration reflects the epidemiological reality on the ground: the country has borne the heaviest burden of illness and death, making it the logical priority for vaccine distribution. The remaining 15 percent will be divided among the eight other nations, each facing their own escalating case counts.
The vaccines themselves come from a coalition of donors: European countries, the United States, Canada, and Gavi, a public-private partnership that has long served as a mechanism for financing vaccine purchases in low-income nations. This multinational sourcing arrangement echoes the collaborative infrastructure that emerged during the COVID-19 pandemic, when wealthy nations and international organizations worked to channel doses to countries with limited purchasing power. The WHO has also established a broader support scheme designed to deliver not just vaccines but diagnostic tests and treatments to the world's most vulnerable populations.
The announcement arrives against a backdrop of earlier criticism directed at the WHO for what many observers characterized as a sluggish vaccine response. In September, after facing sustained pressure, the organization cleared Bavarian Nordic's mpox vaccine for use and signaled openness to considering LC16, a vaccine developed by Japan's KM Biologics, as an additional option. These approvals expanded the toolkit available to countries racing to contain spread, though questions about manufacturing capacity and equitable distribution remained pressing.
What the allocation represents, in practical terms, is an attempt to prevent the outbreak from metastasizing further across the continent. With more than 46,000 cases already documented and deaths exceeding 1,000, the window for containment is narrowing. The vaccine doses now being directed to these nine countries will need to reach the populations most at risk—healthcare workers, close contacts of confirmed cases, and communities experiencing active transmission—quickly enough to bend the curve of infection. The success of this effort will depend not only on the availability of doses but on the capacity of health systems in each country to deliver them, track their impact, and maintain the surveillance infrastructure necessary to monitor for new variants or resurgences.
Notable Quotes
The WHO declared mpox a global public-health emergency for the second time in two years in August after a new variant of the virus, called clade Ib, spread from the Democratic Republic of Congo to neighbouring countries.— WHO statement
Want the full story?
Read the original at The Globe and Mail ↗
Health & Medicine